Recently, we developed a novel and simple synthesis route to create nanosized (~ 5 nm) silver nanoparticles (NP) embedded in a biocompatible nanogel (NG) comprised of degradable, natural polymers, namely, dextran and lysozyme. In this study, we prepare hybrid nanogels with varying lysozyme content, evaluate their potential to reduce Ag NPs in situ (UV-Vis, cryo-TEM, TGA and FTIR) and determine their antibacterial properties against Escherichia coli and Staphylococcus aureus. Lysozyme enhances nucleation and stabilization of Ag NPs while limiting their growth. As lysozyme concentration increases, larger nanogels with greater loading of smaller Ag NPs are obtained. The antibacterial properties of hybrid NGs depend upon nanogel type and bacterial conditions. Hybrid nanogels with the largest Ag NPs show the lowest minimum inhibition concentration (MIC). However, the greatest bacterial killing efficiency (up to 100%) occurs within one hour if the bacteria are exposed to hybrid nanogels with smaller Ag NPs while agitating the medium. These results suggest that nanogel properties as well as antibacterial activity can be tuned by varying lysozyme content. By targeting drug delivery (e.g., ligand grafted surface), these nanogels can be used to prevent biofilm formation and control infection without the complications (i.e., over exposure) associated with classical antibiotic delivery platforms.